• Title/Summary/Keyword: Pharmaceutical Market

Search Result 187, Processing Time 0.026 seconds

Establishment of Quantitative Method for Generic Drugs in Korea Pharmaceutical Codex Monograph (공정서 수재 의약품의 정량법 개선에 관한 연구)

  • Song, JaeYong;Jang, JinSeob;Jang, SeungEun;Kim, SunHoi;Kim, InKyu;Lee, GilBong;Lee, JeaMan;Kim, YongHee
    • YAKHAK HOEJI
    • /
    • v.56 no.5
    • /
    • pp.288-292
    • /
    • 2012
  • The aim of the paper is to ameliorate old research methods of Korean Pharmaceutical Codex to adjust the newest scientistic level which is necessary to maintain quality of medical supplies effectively. After reviewing result of Establishment of Dissolution Specifications for Generic Drugs in Korea Pharmaceutical Codex Monograph, there are two items chosen for the methods - Establishment of Dissolution Specifications for Generic Drugs in Korea Pharmaceutical Codex Monograph which KFDA researched in 2010, arranged new measuring standard by having an experiment to set measuring method after obtaining each item. According to the result, The experiment includes a measuring method of two items; Nafronyl Oxalate Capsules, and Ticlopidine Hydrochloride Tablets. The research is ameliorated by research methods through several experiments such as High Performance Liquid Chromatography validation, preparing items, implement of trial-experiment and authentic experiment, and experiment on measuring method of regulations of Korea Pharmaceutical Codex. The experiments are taken opinions of experts in KFDA into consideration and wrote out a report of the new measuring method on each last item. The report is combined as each two experiment sections of analyzing method to maintain the quality on the basis of the research in 2010 on setting of dissolution specifications for oral solid dosage forms. The result of measuring method of medical supplies through modernizing trial method of oral solid dosage forms is available to be accurate. In conclusion, this study could contribute to promotion of public health by organizing a basis for safe and high quality of medical supplies in domestic market.

A Comparative Study on the Excess Returns of Growth Stocks and Value Stocks in the Korean Stock Market (한국 주식시장에서 성장주와 가치주의 초과수익률 비교 연구)

  • Koh, Seunghee
    • Journal of the Korea Convergence Society
    • /
    • v.9 no.7
    • /
    • pp.213-222
    • /
    • 2018
  • This study attempts to empirically investigate the excess returns of growth stocks in the Korean stock market comparing with those of value stocks. Recently, a few of IT and bio-pharmaceutical stocks with high growth potentials have accomplished dramatically high returns in the Korean stock market. Whereas, important prior studies in this line have observed negative excess returns from investment of growth stocks on average. And a few studies have reported that the distribution of excess returns from growth stocks is not normal but positively skewed. Empirical results of the present study are consistent with those of prior studies. Interestingly, the present study observed serial inverse correlation between excess returns of growth stocks and value stocks. Also, regardless of growth or value stocks, the stocks with higher PEG(=PER/ROE) showed higher excess returns.

Diversification Strategy through Market Creation: The Case of CJ Group

  • Jeong, Jaeseok;Kim, Nam Jung;Lim, Hyunjoo;Kang, Hyoung Goo;Moon, Junghoon
    • Asia Marketing Journal
    • /
    • v.15 no.4
    • /
    • pp.1-32
    • /
    • 2014
  • The purpose of this paper is to investigate upon a diversification strategy through market creation of CJ Group, which has contributed in positioning of the firm as one of the leading conglomerates in South Korea. With such objective, the background of CJ Group, followed by its business diversification strategies were explored, with reference to several case studies. The history of CJ Group began with establishment of CheilJedang Industrial Corporation in 1953, as the first domestic sugar producer and exporter of South Korea. The corporation gradually expanded its business ever since at both national and global level, to include the fields of food production, pharmaceutical, biotechnology, and life chemicals. Later, CheilJedang (CJ) Group was established as an affiliate of CheilJedang Industrial Corporation. With such independence, extension of business has been witnessed across the industries of media, entertainment, finance, information technology and distribution. Thus, the current CJ Group pursues to define itself as a progressive global living culture company with four major business categories from food and food service, biotechnology, entertainment and media, and logistics. Despite its success in today's market, CJ Group underwent hardships in its business diversification in 1990s due to indiscreet management, along with the Asian financial crisis. Here, many firms overcame the financial difficulties by taking advantage of the exchange rate for overseas expansion. Though, CJ Group tried to differentiate itself by focusing on the domestic market by creating something out of nothing. Hence, CJ Group takes a unique position among many cases of business diversification and their categorization. In an effort to identify and classify the types of growth experienced by the top 30 companies in South Korea, the firms were categorized into four groups according to their diversification strategies adapted after the Asian financial crisis. Based on the mode and time of entry, corporations were identified either as the 'Explorer', 'Invader', 'Venture Capitalist', or 'Assimilator'. Here, the majority of the firms showed the qualities of Invader, entering mature markets through large-scaled mergers and acquisitions. However, CJ Group was the only firm that was categorized as an Explorer, for its focus on the newly emerging service sector in culture-contents industry. This diversification strategy through market creation is worth examining, due to its contribution in generating simultaneous growth between the market and the company itself. Diverse brands of CJ Group have been referred to as case studies in this regard, from 'Hatban', 'Cine de Chef', 'VIPS' to 'CJ GLS'. These four businesses, each to represent processed food, film, restaurant service, and logistics industries respectively, show CJ Group's effectiveness in creating a whole new category of goods and services that are innovative. In fact, such businesses not only contributed in advancement of consumers' wellbeing, but toward generating additional value and employment. It is true that the diversification strategy of CJ Group requires long-term capital investment with high risk, compared to the other strategies mentioned in the paper. However, this model does create high employment and additional values that are positive to both the society and the firm itself. Therefore, the paper comes to a conclusion that the diversification strategy through market creation conveys the most positive impact relative to the others.

  • PDF

Pharmacokinetics of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) Following Intravenous, Intramuscular and Subcutaneous Administration of HM10411 and Filgrastim to Rats and Mice (인과립구 콜로니 자극인자 제제인 HM10411와 필그라스팀의 정맥, 근육 및 피하 주사시 흰쥐와 마우스에서의 약물 동태)

  • Kim, In-Wha;Lee, Sang-Hoon;Kim, Young-Min;Jung, Sung-Youb;Kwon, Se-Chang;Lee, Gwan-Sun;Chung, Suk-Jae;Shim, Chang-Koo
    • Journal of Pharmaceutical Investigation
    • /
    • v.31 no.2
    • /
    • pp.89-94
    • /
    • 2001
  • The pharmacokinetics of recombinant human granulocyte colony stimulating factor (rhG-CSF) following intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) administration of HM1041l-lyo and HM10411-liq (lyophilized and liquid formulations of rhG-CSF, recently under development by Hanmi Pharmaceutical Company) were studied in rats, and compared with that of Filgrastim (conventional formulation of rhG-CSF on market). The plasma concentration of rhG-CSF was quantified using a specific ELISA. The pharmacokinetic parameters of rhG-CSF, after i.v., i.m. and s.c. administration of Filgrastim, HM1041l-lyo and HM1041l-liq to rats at a rhG-CSF dose of $10\;{\mu}g/kg$, were almost identical among the three formulations. No dose-dependency was observed in the pharmacokinetic parameters of rhG-CSF following i.v. administration in the dose range of $5{\sim}100\;{\mu}g/kg$. rhG-CSF, after i.v. administration of the three preparations at a dose of $10\;{\mu}g/kg$ to rats, was detected at low levels in all of the body tissues with highest tissue/plasma ratio of $0.46{\sim}0.51$ for the kidney at 30 min after the administration. The pharmacokinetics of rhG-CSF, after i.v. administration to mice at a dose of $10\;{\mu}g/kg$, were comparable among the three formulations. In conclusion, HM10411-lyo and HM10411-liq exhibited similar pharmacokinetics for rhG-CSF with Filgrastim regandless of animal species. Considering the fact that HM10411 series, contrary to Filgrastim, are proteins lacking a methionine residue, the methionine moiety in rhG-CSF molecule does not appear to influence the pharmacokinetics of the protein significantly.

  • PDF

The factors affecting therapeutical diversification of domestic pharmaceutical companies in Korea (국내 제약기업의 치료제 질환분야 다각화 결정요인)

  • Jung, Seung-Yeon;Lee, Sang-Won
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.19 no.10
    • /
    • pp.490-497
    • /
    • 2018
  • This study is to identify factors influencing therapeutic diversification strategy for Korean pharmaceutical companies. So, it purposes to find deciding factors for companies to adopt strategy for diversification or specialization. In this paper, we set six factors that are expected to influence diversification. The factors are asset scale, sales, profitability, and growth potential. Also, we included number of employees and SG&A cost ratio as factors that reflect business characteristics. We analyzed the impacts of each factor on diversification and found a relationship amongst each other. In this paper, regression analysis is applied with forward selection method, considering that it takes 5 years for companies to decide on diversification strategy. As a result, asset scale, the number of employees and profitability have significantly influenced decisions of diversification at t-1 time, and growth potential was significantly influenced at t-2 time. Korean pharmaceutical companies generally tend to go with specialization model if they have larger asset scale, higher profitability and growth potential. However, they have tendency to decide on diversification strategy, if they have large number of employees. Overall, the result of this study is expected to provide useful information for Korean pharmaceutical companies to set the suitable strategy for their situation to become a competitive company in global pharmaceutical market.

The economic effect of Korea-EFTA Mutual Recognition Agreement in the pharmaceutical industry using Conditional Valuation Method (CVM) (조건부가치평가법(CVM)을 이용한 한-EFTA간 제약 산업 상호인정협약 체결의 경제적 효과 분석)

  • Kwon, Tae-Hyuk;Lee, Sang-Won
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.19 no.5
    • /
    • pp.389-398
    • /
    • 2018
  • An MRA is considered to be an important policy tool within the WTO for overcoming technical barriers to trade. A number of studies on the economic impact of MRAs have demonstrated their positive economic effects. However, no studies have been conducted on MRAs in the pharmaceutical industry since analysis has been limited to industries as a whole or certain industries where some data were accumulated. Therefore, this paper analyzed the economic impact of MRAs for GMP inspection exemption in the pharmaceutical industry through the Conditional Valuation Method (CVM), a valuation technique for non-market goods. Pharmaceutical companies were asked whether or not they were willing to pay for the Korea-EFTA MRA through double-bounded dichotomous choice (DBDC) questions. The final WTP was estimated using the utility difference model developed by Hanemann (1984). As a result, annual economic effects on the pharmaceutical industry were estimated to be between KRW7.03 billion to KRW15.8 billion.

A Study on the Visual Characteristics of Korean Pharmaceutical Companies' CI Symbol Marks (국내 제약회사 심벌마크의 시각적 특징 연구)

  • Hong, Il-Yang
    • The Journal of the Korea Contents Association
    • /
    • v.16 no.9
    • /
    • pp.443-450
    • /
    • 2016
  • Korean biopharmaceutical industry is a high value-added industries of the country as a key business strategy of the country. The overseas market is accelerating rapidly due to drug demand according to population aging, new drug R&D investment performance visualization, changes in biopharmaceutical R&D center, strategic foreign technology exports, and the active support of government. Therefore, the domestic pharmaceutical companies also should enhance the competitiveness as global pharmaceutical companies and need to build the image of their own company that can be trusted by consumers. This study compared and analyzed visual characteristics shown in the CI symbol mark and age-specific preferences of domestic pharmaceutical companies recognizing the importance of CI as a marketing tool. As a result, preference for the symbol mark had been shown to be significantly higher preference of the old logotype as the age group is higher being proportional to awareness. In addition, the picture-type symbol mark was totally preferred rather than the word mark. Among the picture-type symbol mark, the form of the nature was strongly preferred rather than abstract form. The company also requires a sense of responsibility for recognizing changes in the mass to the globalization. It is hoped that this study will help to develop symbol mark direction as the basis for the identity strategies to improve the image of domestic pharmaceutical companies with global competitiveness.

Pharmaceutical study on the Compressed Tablets. Hardness, Friability, Disintegration time and Coefficient of Variance of Compressed tablets (정제류(錠劑類)의 제제학적(製劑學的) 연구(硏究) -경도(硬度), 마손도(磨損度), 붕해시간(崩解時間) 및 변동계수(變動係數)에 대(對)하여)

  • Kim, Soo-Uck;Suh, Sung-Hun;Lee, Hyun-U
    • Journal of Pharmaceutical Investigation
    • /
    • v.2 no.2
    • /
    • pp.18-33
    • /
    • 1972
  • Pharmaceutical Study on the Compressed tablets. Hardness, Friability, Disintegration time and Coefficient of Variance of Compressed tablets. Soo Uck Kim, Sung Hoon seo and Hyun Woo Lee (Department of Pharmaceutics, College of Pharmacy, Kyung Hee University) In order to know Hardness, Friability, Disintegration time and Coefficient of variance of the pharmaceutical tablets the 135 tablets sampled from market were tested in the paper. The samples tested in this paper were as follows: Antipyretics and Analgetics 41 Stomach and Digestives 22 Antituberculars 19 Vitamins 12 Sulfa drugs 9 Others (Antihistaminics etc) 32 Total 135 The results of the investigation are shown in table 1-8, Fig 1-Fig 6. Mean values of Hardness, Friability, Disintegration time and Coefficient of variance in each pharmaceutical preparation are as follows. Antipyretics and Analgetics : Hardness(kg) = 5.83 Antipyretics and Analgetics : Friabil.(%) = 0.82 Antipyretics and Analgetics : Disint.t.(min) = 5.28' Antipyretics and Analgetics : Coeff. of V.(%) = 2.90 Stomach and Digestives : Hardness(kg) = 4.11 Stomach and Digestives : Friabil.(%) = 0.71 Stomach and Digestives : Disint.t.(min) = 3.43' Stomach and Digestives : Coeff. of V.(%) = 2.76 Antituberculars : Hardness(kg) = 4.78 Antituberculars : Friabil.(%) = 0.52 Antituberculars : Disint.t.(min) = 4.32' Antituberculars : Coeff. of V.(%) = 2.99 Vitamins : Hardness(kg) = 1.60 Vitamins : Friabil.(%) = 0.43 Vitamins : Disint.t.(min) = 4.10' Vitamins : Coeff. of V.(%) = 3.19 Sulfa drugs : Hardness(kg) = 4.77 Sulfa drugs : Friabil.(%) = 0.37 Sulfa drugs : Disint.t.(min) = 3.10' Sulfa drugs : Coeff. of V.(%) = 2.09 Others : Hardness(kg) = 2.40 Others : Friabil.(%) = 0.66 Others : Disint.t.(min) = 2.19' Others : Coeff. of V.(%) = 3.10 The following summeries might be shown; 1. Ranges of Hardness, Friability, Disintegration time and Coefficient of variance are respectively 1.6 to 5.38 kg, 0.37 to 0.82%, 2 minut 19 second to 5 minut 28 second and 2.09 to 3.10%. 2. According to the results, it could be indicated that higher Hardness shows lower Friability. 3. Against the general conception between Hardness and Disintegration time, higher Hardness shows lower Disintegration time. 4. It seems that higher mean weight shows lowcr Coefficient variance.

  • PDF

Pharmacognostical Studies on a Folk Medicine "SinKyungCho" (민간약 신경초의 생약학적 연구)

  • Bae, Ji-Yeong;Goo, Young-Min;Park, Jong Hee;Ahn, Mi-Jeong
    • Korean Journal of Pharmacognosy
    • /
    • v.44 no.4
    • /
    • pp.326-331
    • /
    • 2013
  • A Korean folk medicine, "SinKyungCho" has been used to cure common cold and rheumatis. While this crude drug has similar morphological feature to that of Rubia species, the botanical origin has never been studied pharmacognostically. Therefore, in order to clarify the botanical origin of "SinKyungCho", the morphological and anatomical characteristics of Rubia species growing in Korea, i.e. R. akane, R. chinensis var. glabrescens, R. cordifolia var. pratensis, R. cordifolia var. sylvatica were studied. Especially, differing from the other three species, R. cordifolia var. pratensis has 2-4 cork cell layers under the endodermal cell layer. R. cordifolia var. sylvatica showed the largest number of parenchyma cell layers in cortex by 8-17. While the average ratio of stele to root transverse section is over 45% for R. akane and R. cordifolia var. pratensis, the ratio is under 45% for R. chinensis var. glabrescens and R. cordifolia var. sylvatica. According to these morphological criteria, the folk medicine "SinKyungCho" from Korean traditional market was proved to be the underground part of R. akane.

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

  • Li, Rihua;Lim, Soo-Jeong;Choi, Han-Gon;Lee, Mi-Kyung
    • Journal of Pharmaceutical Investigation
    • /
    • v.40 no.spc
    • /
    • pp.63-73
    • /
    • 2010
  • Solid lipid nanoparticles (SLNs) have emerged to combine the advantages of polymeric nanoparticles and lipid emulsions in early 1990s. SLNs can present several desirable properties derived from the solid state core. When formulating SLNs, there should be careful considerations about the physical state of the inner solid lipid core and its polymorphism and supercooling behavior. In this review, SLNs were compared to lipid emulsion and emulsion of supercooled melt to understand the unusual behaviors compared to lipid emulsions and to have insights into stability and release mechanism. SLNs have been regarded as biocompatible system because lipids are usually well-tolerable ingredients than polymers. Several studies showed good tolerability of SLNs in terms of cytotoxicity and hemolysis. Similar to various other nanoparticulate drug delivery systems, SLNs can also change biodistribution of the incorporated drugs in a way to enhance therapeutic effect. Most of all, large scale production of SLNs was extablished wihtout using organic solvents. Although there is no SLN product in the market till date, several advantagious properties of SLNs and the progress we have seen so far would make commercial product of SLNs possible before long and encourage research community to apply SLN-based formulations for water-insoluble drugs.